Quick viewing(Text Mode)

Interactions with Protease Inhibitors Charts Revised February 2018

Interactions with Protease Inhibitors Charts Revised February 2018

www.-druginteractions.org

Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium          Ertapenem          Bupivacaine          Erythromycin          Cisatracurium          Ethambutol                   Ethionamide                   Flucloxacillin                   Gentamicin                   /Cilastatin                   Isoniazid                   Kanamycin                            Linezolid                   Meropenem                            Rocuronium          Moxifloxacin                   Nitrofurantoin          Sufentanil                   Suxamethonium (succinylcholine)          Para-aminosalicylic acid          Tetracaine                   Thiopental          for distribution. for Pyrazinamide                   Rifabutin          Vecuronium          Rifampicin          Analgesics Rifapentine          Alfentanil          Rifaximin          Aspirin          Spectinomycin          Buprenorphine          Streptomycin          Celecoxib          Sulfadiazine                   Telithromycin                            Trimethoprim/Sulfamethoxazole          Diamorphine (diacetylmorphine)          Vancomycin          Diclofenac          Dihydrocodeine          Anti-coagulant, Anti-platelet and Fibrinolytic Fentanyl          Acenocoumarol          Apixaban                   Aspirin (anti-platelet)          Hydromorphone                   Ibuprofen          Dabigatran                   Dalteparin                                     Edoxaban          Naproxen          Not only. use For personal distribution. Eltrombopag          Nimesulide          Enoxaparin                   Fondaparinux          Paracetamol (Acetaminophen)          Heparin          (Meperidine)          Phenprocoumon          Piroxicam                            Rivaroxaban          Streptokinase                                     Warfarin                   (Ergamisol)                                              Ethosuximide                            Lacosamide                   Lamotrigine                   Levetiracetam          sodium          Oxcarbazepine                   (Phenobarbitone)          Antiarrhythmics          Amiodarone                   Bepridil                   Disopyramide          (Divalproex)          Dofetilide          Vigabatrin          Flecainide          Zonisamide          Lidocaine (Lignocaine)          Mexiletine                                                                Antibacterials Amikacin                            Amoxicillin                   Ampicillin                   Azithromycin                   Bedaquiline                   Capreomycin          for Not only. use For personal for distribution. Not only. use For personal          Cefalexin                   Cefazolin                   Cefixime                   Cefotaxime          Mianserine          Ceftazidime          Milnacipran          Ceftriaxone                   Chloramphenicol                                     Clarithromycin                   Clavulanic acid                   Clindamycin                   Clofazimine                   Cloxacillin          Tranylcypromine                                                               

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and ATV (Reyataz®) IDV (Crixivan®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ®  Cobi (Tybost®) LPV (Kaletra ) alteration of drug dosage or timing of administration © Liverpool Drug Interaction Group, University of Liverpool Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® ® Additional action/monitoring or dosage adjustment is DRV (Prezista ) RTV (Norvir ) We aim to ensure that information is accurate and consistent with current knowledge unlikely to be required ® and practice. However, the University of Liverpool and its servants or agents shall not SQV (Invirase )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this FPV ® ® publication whether arising from negligence or otherwise howsoever or for any (Telzir , Lexiva ) TPV (Aptivus®) There are no clear data, actual or theoretical, to indicate consequences arising therefrom. The University of Liverpool expressly exclude  whether an interaction will occur

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 2 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anti-diabetics /Neuroleptics Acarbose                   Empagliflozin                   Exanatide                            Glibenclamide (Glyburide)                   Gliclazide                   Glimepiride                   Glipizide                   Insulin                   Linagliptin                  

Liraglutide                            Metformin                   Nateglinide                   Pioglitazone                   Repaglinide                   Rosiglitazone                  

Saxagliptin          distribution. for          Sulpiride Sitagliptin                            Tolbutamide          Tiapride          Vildagliptin                                                       Antivirals          Aciclovir                   Adefovir                            Boceprevir                   Cidofovir                   Daclatasvir                   Elbasvir/Grazoprevir                   Entecavir                   Famciclovir                            Ganciclovir                   Glecaprevir/Pibrentasvir          distribution. For personal use only. Not Not only. use For personal distribution.          Ledipasvir/Sofosbuvir          Ombitasvir/Paritaprevir/r                   Ombitasvir/Paritaprevir/r + Dasabuvir          Cetirizine          Oseltamivir          Chlorphenamine          Ribavirin                   Rimantadine          Simeprevir          Fexofenadine          Sofosbuvir          Levocetirizine          Sofosbuvir/Velpatasvir          Loratadine          Sofosbuvir/Velpatasvir/Voxilaprevir                   Telaprevir          Terfenadine          Telbivudine          Antimigraine Agents Valaciclovir                   Zanamivir                   //                                                                         Amodiaquine                   Artemisinin                                                                Chloroquine                   Diloxanide                            (oral)          Halofantrine          Midazolam (parenteral)          Lumefantrine                   Mefloquine                                                               

Miltefosine          for Not only. use For personal for distribution. Not only. use For personal                   Beta Blockers                                     Primaquine                   Proguanil                            Pyrimethamine                   Quinine                                     Sulfadoxine                  

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and ATV Atazanavir (Reyataz®) IDV Indinavir (Crixivan®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ®  Cobi Cobicistat (Tybost®) LPV Lopinavir (Kaletra ) alteration of drug dosage or timing of administration © Liverpool Drug Interaction Group, University of Liverpool Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® ® Additional action/monitoring or dosage adjustment is DRV Darunavir (Prezista ) RTV Ritonavir (Norvir ) We aim to ensure that information is accurate and consistent with current knowledge unlikely to be required ® and practice. However, the University of Liverpool and its servants or agents shall not Fosamprenavir SQV Saquinavir (Invirase )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this FPV ® ® publication whether arising from negligence or otherwise howsoever or for any (Telzir , Lexiva ) TPV Tipranavir (Aptivus®) There are no clear data, actual or theoretical, to indicate consequences arising therefrom. The University of Liverpool expressly exclude  whether an interaction will occur

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 3 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Bronchodilators Cytotoxics (continued) Aclidinium          Mercaptopurine                   Mesna                            Glycopyrronium bromide          Mitoxantrone                   Nilotinib          Ipratropium bromide          Oxaliplatin          Montelukast          Paclitaxel          Olodaterol          Pazopanib          Roflumilast          Procarbazine                   Rituximab         

Salmeterol          Sorafenib                   Sunitinib          Tiotropium bromide                   Umeclidinium bromide          Temsirolimus                   Topotecan          Toremifene          Channel Blockers Amlodipine          Vinblastine          Vincristine          Diltiazem          distribution. for Vorinostat Felodipine                            Erectile Dysfunctional Agents          Sildenafil (Erectile Dysfunction)          Nisoldipine          Tadalafil (Erectile Dysfunction)                   Vardenafil                   Gastrointestinal Agents Contraceptives/HRT          Desogestrel (COC)          Aluminium hydroxide          Desogestrel (POP)          Antacids          Drospirenone (COC)          Bisacodyl          Drospirenone (HRT)                   Dydrogesterone (HRT)                            Esomeprazole          Ethinylestradiol          Famotidine          Etonogestrel (implant)          Lactulose          Etonogestrel (vaginal ring)          Lansoprazole          Gestodene (COC)          Loperamide          Levonorgestrel (COC)          Mesalazine          Levonorgestrel (emergency contraception)          Omeprazole          distribution. For personal use only. Not Not only. use For personal distribution. Levonorgestrel (HRT)          Pantoprazole          Levonorgestrel (implant)                   Levonorgestrel (IUD)          Rabeprazole          Levonorgestrel (POP)          Ranitidine          Senna Medroxyprogesterone (depot injection)                   Medroxyprogesterone (oral)          Gastrointestinal Agents (anti-emetics) Norelgestromin (patch)                   Norethisterone [Norethindrone] (COC)                   Domperidone          Norethisterone [Norethindrone] (HRT)          Dronabinol          Norethisterone [Norethindrone] (IM depot)                   Norethisterone [Norethindrone] (POP)                   Norgestimate (COC)                   Norgestrel (COC)                   Norgestrel (HRT)          Ulipristal          /Supplements/Vitamins Cytotoxics African potato                   Anastrozole          Ascorbic Acid (Vitamin C)          Asparaginase          ’s claw (Uncaria tomentosa)          Bexarotene          Colecalciferol (vitamin D3)          Bleomycin          Cubeb pepper (Piper cubeba)          Bortezomib          Cyanocobalamin          Caprecitabine          Echinacea          Carboplatin          Eucalyptus globulus          Chlorambucil          Folic acid          Cisplatin          Garlic          Cyclophosphamide          (Zinigiber officinale)          Cytarabine          biloba          Dacarbazine          root (Hydrastis canadensis)          Dactinomycin          Grapefruit juice          Dasatinib          (Humulus lupulus)          Daunorubicin          Inula racemosa          Docetaxel          Iodine          Doxorubicin          Iron supplements          Droloxifene          (Glycyrrhiza glabra)          Epirubicin          For personal use only. Not for distribution. For personal use only. Not for Not only. use For personal for distribution. Not only. use For personal Malabar nut tree          Erlotinib                   Estramustine          Milk thistle          Etoposide                   Everolimus          Phytomenadione (vitamin K)          Exemestane          Pyridoxine (vitamin B6)          Fludarabine                   Fluorouracil          Retinol (vitamin A)          Formestane          Riboflavin (vitamin B2)          Gefitinib          Saw palmetto (Serenoa repens)          Gemcitabine          Seville orange juice          Ifosfamide          St John's Wort          Imatinib          Thiamine (vitamin B1)          Irinotecan          (Curcuma longa)          Lapatinib                   Letrozole          Vitamin E         

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and ATV Atazanavir (Reyataz®) IDV Indinavir (Crixivan®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ®  Cobi Cobicistat (Tybost®) LPV Lopinavir (Kaletra ) alteration of drug dosage or timing of administration © Liverpool Drug Interaction Group, University of Liverpool Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® ® Additional action/monitoring or dosage adjustment is DRV Darunavir (Prezista ) RTV Ritonavir (Norvir ) We aim to ensure that information is accurate and consistent with current knowledge unlikely to be required ® and practice. However, the University of Liverpool and its servants or agents shall not Fosamprenavir SQV Saquinavir (Invirase )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this FPV ® ® publication whether arising from negligence or otherwise howsoever or for any (Telzir , Lexiva ) TPV Tipranavir (Aptivus®) There are no clear data, actual or theoretical, to indicate consequences arising therefrom. The University of Liverpool expressly exclude  whether an interaction will occur

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 4 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Hypertension / Heart Failure Agents Other Aliskiren          Acetazolamide          Ambrisentan          Acitretin                   (Epinephrine)          Bendroflumethiazide          Alendronic Acid          Bosentan                   Candesartan                   Captopril                   Chlortalidone                   Cilazapril          Biperiden                   citrate          Digoxin         

Calcium                   Carbimazole                   Clomifene          Enalapril                   Epoprostenol                   Eprosartan          Denosumab                            Hydralazine                  

Hydrochlorothiazide          distribution. for          Iloprost                   Indapamide          Goserelin          Irbesartan          Ibandronic acid          Isosorbide dinitrate                   Ivabradine          Leuprorelin                   Levothyroxine          Lacidipine                   Lercanidipine          Mannitol          Lisinopril          Methylphenidate          Losartan          Modafinil          Macitentan                            Naltrexone          Metolazone          Neostigmine          Olmesartan          Nicorandil          Perindopril          Orlistat                   Penicillamine          Quinapril          Ramipril                   Ranolazine          Pilocarpine          Riociguat          Potassium         

Sacubitril          Not only. use For personal distribution. Probenecid          Selexipag          Propylthiouracil          Sildenafil (PAH)          Protamine sulphate          Sodium nitroprusside          Pyridostigmine                   Strontium ranelate          Tadalafil (PAH)          Sulfasalazine          Telmisartan                   Terazosin          Thalidomide          Torasemide          Tranexamic acid          Trandolapril                   Treprostinil          Zoledronic acid          Valsartan          Overactive Bladder Agents Xipamide          Darifenacin          Illicit/Recreational Fesoterodine                                     Oxybutynin                   Solifenacin                   Tolterodine          Ecstasy (MDMA)          Trospium          GHB (Gamma-hydroxybutyrate_          Oxytocics Heroin          (Ergonovine)          LSD (Lysergic acid diethylamide)          Mifepristone          Mephedrone          Misoprostol          Methamphetamine          Oxytocin          (PCP)          Poppers(Amyl nitrate)          Parkinsonism Agents Immune Modulators          Benserazide          Hydroxyurea ()          Carbidopa          alpha          Levodopa          Interleukin 2 (Aldesleukin)          Peginterferon alfa-2a          Pramipexole          Rasagiline          Immunosuppressants Ropinirole          Anti-thymocyte globulin                   Steroids Basiliximab          Beclometasone          Belatacept          Betamethasone          Budesonide         

Ciclosporin          for Not only. use For personal for distribution. Not only. use For personal Mycophenolate          Clobetasol          Sirolimus          Dexamethasone                   Fludrocortisone          Lipid Lowering Agents Fluocinolone          Fluticasone          Atorvastatin          (oral)          Bezafibrate          Hydrocortisone (topical) Clofibrate                   Ezetimibe          Megestrol acetate          Fenofibrate          Methylprednisolone          Fish oils          Mometasone          Fluvastatin          Nandrolone          Gemfibrozil          Oxandrolone          Lovastatin          Prednisolone          Pitavastatin          Prednisone          Pravastatin          Stanazolol          Rosuvastatin                   Simvastatin          Triamcinolone          Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and ATV Atazanavir (Reyataz®) IDV Indinavir (Crixivan®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ®  Cobi Cobicistat (Tybost®) LPV Lopinavir (Kaletra ) alteration of drug dosage or timing of administration © Liverpool Drug Interaction Group, University of Liverpool Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® ® Additional action/monitoring or dosage adjustment is DRV Darunavir (Prezista ) RTV Ritonavir (Norvir ) We aim to ensure that information is accurate and consistent with current knowledge unlikely to be required ® and practice. However, the University of Liverpool and its servants or agents shall not Fosamprenavir SQV Saquinavir (Invirase )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this FPV ® ® publication whether arising from negligence or otherwise howsoever or for any (Telzir , Lexiva ) TPV Tipranavir (Aptivus®) There are no clear data, actual or theoretical, to indicate consequences arising therefrom. The University of Liverpool expressly exclude  whether an interaction will occur

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NNRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

RPV + RPV + EFV ETV NVP RPV F/TAF EFV ETV NVP RPV F/TAF Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium      Ertapenem      Bupivacaine      Erythromycin      Cisatracurium      Ethambutol      Desflurane      Ethionamide      Dexmedetomidine      Flucloxacillin      Enflurane      Gentamicin      Ephedrine      Imipenem/Cilastatin      Halothane      Isoniazid      Isoflurane      Kanamycin      Levofloxacin Ketamine           Linezolid      Nitrous oxide      Meropenem      Propofol      Metronidazole      Rocuronium      Moxifloxacin      Sevoflurane      Nitrofurantoin      Sufentanil      Ofloxacin      Suxamethonium (succinylcholine)      Para-aminosalicylic acid      Tetracaine      Penicillins      Thiopental      Pyrazinamide      Tizanidine      Rifabutin      Vecuronium      Rifampicin      Analgesics Rifapentine      Alfentanil      Rifaximin      Aspirin      Spectinomycin      Buprenorphine      Streptomycin      Celecoxib      Sulfadiazine      Telithromycin Codeine           Tetracyclines      Dextropropoxyphene      Trimethoprim/Sulfamethoxazole      Diamorphine (diacetylmorphine)      Vancomycin      Diclofenac      Dihydrocodeine      Anti-coagulant, Anti-platelet and Fibrinolytic Fentanyl      Acenocoumarol      Hydrocodone      Apixaban      Aspirin (anti-platelet) Hydromorphone           Clopidogrel      Ibuprofen      Dabigatran      Mefenamic acid      Dalteparin      Methadone      Dipyridamole      Morphine      Edoxaban     

Naproxen      distribution. for Not only. use For personal istribution. Eltrombopag      Nimesulide      Enoxaparin      Oxycodone      Fondaparinux      Paracetamol (Acetaminophen)      Heparin      Pethidine (Meperidine)      Phenprocoumon      Piroxicam      Prasugrel      Tramadol      Rivaroxaban      Anthelmintics Streptokinase      Albendazole      Ticagrelor      Diethylcarbamazine      Warfarin      Ivermectin      Anticonvulsants Levamisole (Ergamisol)      Carbamazepine      Mebendazole      Clonazepam      Niclosamide      Ethosuximide      Oxamniquine      Gabapentin     

For personal use only. Not for d Not only. use For personal Lacosamide     

Praziquantel      Pyrantel      Lamotrigine      Suramin sodium      Levetiracetam      Oxcarbazepine      Triclabendazole      Phenobarbital (Phenobarbitone)      Antiarrhythmics Phenytoin      Amiodarone      Pregabalin      Bepridil      Topiramate      Disopyramide      Valproate (Divalproex)      Dofetilide      Vigabatrin      Flecainide      Zonisamide      Lidocaine (Lignocaine)      Antidepressants Mexiletine      Agomelatine      Propafenone      Amitriptyline      Quinidine      Bupropion      Antibacterials Citalopram      Amikacin      Clomipramine      Amoxicillin      Desipramine      Ampicillin      Doxepin      Azithromycin      Duloxetine      Bedaquiline      Escitalopram      Capreomycin      Fluoxetine      Fluvoxamine      Cefalexin      for distribution. Not only. use For personal Cefazolin      Imipramine      Lithium      Cefixime      Maprotiline      Cefotaxime      Mianserine      Ceftazidime      Milnacipran      Ceftriaxone      Mirtazapine      Chloramphenicol      Nefazodone      Ciprofloxacin      Nortriptyline      Clarithromycin      Paroxetine      Clavulanic acid      Phenelzine      Clindamycin      Reboxetine      Clofazimine      Sertraline      Cloxacillin      Tranylcypromine      Cycloserine      Trazodone      Dapsone      Trimipramine      Doxycycline      Venlafaxine     

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and EFV (Sustiva®, Stocrin®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ® ETV (Intelence )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool Potential interaction likely to be of weak intensity. ® Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF NVP (Viramune ) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge RPV (Edurant®) unlikely to be required and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any RPV + Rilpivirine// There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude F/TAF (Odefsey ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NNRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 2 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

RPV + RPV + EFV ETV NVP RPV F/TAF EFV ETV NVP RPV F/TAF Anti-diabetics Antipsychotics/Neuroleptics Acarbose      Amisulpride      Empagliflozin      Aripiprazole      Exanatide      Asenapine      Chlorpromazine      Glibenclamide (Glyburide)      Clozapine      Gliclazide      Fluphenazine      Glimepiride      Haloperidol      Glipizide      Iloperidone      Insulin      Levomepromazine      Linagliptin      Olanzapine      Liraglutide      Paliperidone      Perazine      Metformin      Periciazine      Nateglinide      Perphenazine      Pioglitazone      Pimozide      Repaglinide      Pipotiazine      Rosiglitazone      Quetiapine      Saxagliptin      Risperidone      Sitagliptin      Sulpiride      Thioridazine      Tolbutamide      Tiapride      Vildagliptin      Ziprasidone      Antifungals Zotepine      Amphotericin B      Zuclopenthixol      Anidulafungin      Antivirals Caspofungin      Aciclovir      Fluconazole      Adefovir      Flucytosine      Amantadine      Boceprevir      Griseofulvin      Cidofovir      Itraconazole      Daclatasvir      Ketoconazole      Elbasvir/Grazoprevir      Miconazole      Entecavir      Nystatin      Famciclovir      Posaconazole      Foscarnet      Ganciclovir Terbinafine           Glecaprevir/Pibrentasvir     

Voriconazole      distribution. for Not only. use For personal istribution. Ledipasvir/sofosbuvir      Antihistamines Ombitasvir/Paritaprevir/r      Astemizole      Ombitasvir/Paritaprevir/r + Dasabuvir      Cetirizine      Oseltamivir      Chlorphenamine      Ribavirin      Diphenhydramine      Rimantadine      Fexofenadine      Simeprevir      Sofosbuvir      Levocetirizine      Sofosbuvir/Velpatasvir      Loratadine      Sofosbuvir/Velpatasvir/Voxilaprevir      Promethazine      Telaprevir      Terfenadine      Telbivudine      Antimigraine Agents Valaciclovir      Almotriptan      Zanamivir      For personal use only. Not for d Not only. use For personal Dihydroergotamine      Anxiolytics/Hypnotics/ Sedatives Ergotamine      Alprazolam      Bromazepam Rizatriptan           Buspirone      Sumatriptan      Chlordiazepoxide      Antiprotozoals Clorazepate      Amodiaquine      Diazepam      Artemisinin      Estazolam      Atovaquone      Flunitrazepam      Benznidazole      Flurazepam      Hydroxyzine      Chloroquine      Lorazepam      Diloxanide      Lormetazepam      Eflornithine      Midazolam (oral)      Halofantrine      Midazolam (parenteral)      Lumefantrine      Oxazepam      Mefloquine      Temazepam      Triazolam      Meglumine antimoniate      Zaleplon      Melarsoprol      Zolpidem           Zopiclone     

Nifurtimox      for distribution. Not only. use For personal Beta Blockers Paromomycin      Atenolol      Pentamidine      Bisoprolol      Primaquine      Carvedilol      Metoprolol Proguanil           Nebivolol      Pyrimethamine      Oxprenolol      Quinine      Pindolol      Sodium stibogluconate      Propranolol      Sulfadoxine      Timolol     

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and EFV Efavirenz (Sustiva®, Stocrin®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ® ETV Etravirine (Intelence )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool Potential interaction likely to be of weak intensity. ® Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF NVP Nevirapine (Viramune ) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge RPV Rilpivirine (Edurant®) unlikely to be required and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any RPV + Rilpivirine/Emtricitabine/Tenofovir alafenamide There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude F/TAF (Odefsey ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NNRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 3 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

RPV + RPV + EFV ETV NVP RPV F/TAF EFV ETV NVP RPV F/TAF Bronchodilators Cytotoxics (continued) Aclidinium bromide      Mercaptopurine      Aminophylline      Mesna      Formoterol      Methotrexate      Glycopyrronium bromide      Mitoxantrone      Indacaterol      Nilotinib      Ipratropium bromide      Oxaliplatin      Montelukast      Paclitaxel      Olodaterol      Pazopanib      Roflumilast      Procarbazine      Salbutamol      Rituximab           Sorafenib      Theophylline      Sunitinib      Tiotropium bromide      Tamoxifen      Umeclidinium bromide      Temsirolimus      Vilanterol      Topotecan      Calcium Channel Blockers Toremifene      Vinblastine      Amlodipine      Vincristine      Diltiazem      Vorinostat      Felodipine      Nicardipine      Erectile Dysfunctional Agents Nifedipine      Sildenafil (Erectile Dysfunction)      Nisoldipine      Tadalafil (Erectile Dysfunction)      Nitrendipine      Vardenafil      Verapamil      Gastrointestinal Agents Contraceptives/HRT Alosetron      Desogestrel (COC)      Aluminium hydroxide      Desogestrel (POP)      Antacids      Drospirenone (COC)      Bisacodyl      Drospirenone (HRT)      Cimetidine      Dydrogesterone (HRT)      Cisapride      Estradiol      Esomeprazole      Famotidine      Ethinylestradiol      Lactulose      Etonogestrel (implant)      Lansoprazole      Etonogestrel (vaginal ring)      Loperamide      Gestodene (COC)      Mesalazine      Levonorgestrel (COC)      Omeprazole      Levonorgestrel (emergency contraception)      istribution. For personal use only. Not for distribution. for Not only. use For personal istribution. Pantoprazole      Levonorgestrel (HRT)      Prucalopride      Levonorgestrel (implant)      Rabeprazole      Levonorgestrel (IUD)      Ranitidine      Levonorgestrel (POP)      Senna      Medroxyprogesterone (depot injection)      Medroxyprogesterone (oral)      Gastrointestinal Agents (anti-emetics) Norelgestromin (patch)      Aprepitant      Norethisterone [Norethindrone] (COC)      Dolasetron      Norethisterone [Norethindrone] (HRT)      Domperidone      Norethisterone [Norethindrone] (IM depot)      Dronabinol      Norethisterone [Norethindrone] (POP)      Granisetron      Metoclopramide Norgestimate (COC)           Ondansetron      Norgestrel (COC)      Prochlorperazine      Norgestrel (HRT)      Herbals/Supplements/Vitamins

Ulipristal      for d Not only. use For personal

Cytotoxics African potato      Aloe vera      Anastrozole      Ascorbic Acid (Vitamin C)      Asparaginase      Cat’s claw (Uncaria tomentosa)      Bexarotene      Colecalciferol (vitamin D3)      Bleomycin      Cubeb pepper (Piper cubeba)      Bortezomib      Cyanocobalamin      Capecitabine      Echinacea      Carboplatin      Eucalyptus globulus      Chlorambucil      Folic acid      Cisplatin      Garlic      Cyclophosphamide      Ginger (Zinigiber officinale)      Cytarabine           Dacarbazine      Goldenseal root (Hydrastis canadensis)      Dactinomycin      Grapefruit juice      Dasatinib      Hops (Humulus lupulus)      Daunorubicin      Inula racemosa      Docetaxel      Iodine      Doxorubicin      Iron supplements      Droloxifene      Liquorice (Glycyrrhiza glabra)      Epirubicin      Malabar nut tree     

Erlotinib      for distribution. Not only. use For personal Menthol      Estramustine      Milk thistle      Etoposide      Nicotinamide      Everolimus      Phytomenadione (vitamin K)      Exemestane      Pyridoxine (vitamin B6)      Fludarabine      Quercetin      Fluorouracil      Retinol (vitamin A)      Formestane      Riboflavin (vitamin B2)      Gefitinib      Saw palmetto (Serenoa repens)      Gemcitabine      Seville orange juice      Ifosfamide      St John's Wort      Imatinib      Thiamine (vitamin B1)      Irinotecan      Turmeric (Curcuma longa)      Lapatanib      Valerian      Letrozole      Vitamin E     

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and EFV Efavirenz (Sustiva®, Stocrin®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ® ETV Etravirine (Intelence )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool Potential interaction likely to be of weak intensity. ® Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF NVP Nevirapine (Viramune ) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge RPV Rilpivirine (Edurant®) unlikely to be required and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any RPV + Rilpivirine/Emtricitabine/Tenofovir alafenamide There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude F/TAF (Odefsey ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NNRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 4 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

RPV + RPV + EFV ETV NVP RPV F/TAF EFV ETV NVP RPV F/TAF Hypertension / Heart Failure Agents Other Aliskiren      Acetazolamide      Ambrisentan      Acitretin      Amiloride      Adrenaline (Epinephrine)      Bendroflumethiazide      Alendronic Acid      Bosentan      Alfuzosin      Candesartan      Allopurinol      Captopril      Atropine      Chlortalidone      Baclofen      Cilazapril      Biperiden      Clonidine           Digoxin      Calcium      Dopamine     

Carbimazole      Doxazosin      Clomifene      Enalapril      Colchicine      Epoprostenol      Cyproterone acetate      Eprosartan      Denosumab      Furosemide      Disulfiram      Hydralazine      Dutasteride      Hydrochlorothiazide      Finasteride      Iloprost      Flibanserin      Indapamide      Goserelin      Irbesartan      Ibandronic acid      Isosorbide dinitrate      Isotretinoin      Ivabradine      Leuprorelin      Labetalol      Levothyroxine      Lacidipine      Magnesium      Lercanidipine      Mannitol      Lisinopril      Methylphenidate      Losartan      Modafinil      Macitentan      Naftidrofuryl      Methyldopa      Naltrexone      Metolazone      Neostigmine      Olmesartan      Nicorandil      Perindopril      Orlistat      Prazosin      Penicillamine Quinapril           Pentoxifylline Ramipril           Ranolazine      Pilocarpine      Riociguat      Potassium      Probenecid     

Sacubitril      distribution. for Not only. use For personal istribution. Selexipag      Propylthiouracil      Sildenafil (PAH)      Protamine sulphate      Sodium nitroprusside      Pyridostigmine      Spironolactone      Strontium ranelate      Tadalafil (PAH)      Sulfasalazine      Telmisartan      Tamsulosin      Terazosin      Thalidomide      Torasemide      Tranexamic acid      Trandolapril      Varenicline      Treprostinil      Zoledronic acid      Valsartan      Overactive Bladder Agents Xipamide      Darifenacin      Illicit/Recreational Fesoterodine      Alcohol      Mirabegron      Amphetamine      Oxybutynin      For personal use only. Not for d Not only. use For personal Cannabis      Solifenacin      Cocaine      Tolterodine      Ecstasy (MDMA)      Trospium      GHB (Gamma-hydroxybutyrate_      Oxytocics Heroin      Ergometrine (Ergonovine)      LSD (Lysergic acid diethylamide)      Mifepristone      Mephedrone      Misoprostol      Methamphetamine      Oxytocin      Phencyclidine (PCP)      Poppers(Amyl nitrate)      Parkinsonism Agents Immune Modulators Apomorphine      Benserazide      Hydroxyurea (Hydroxycarbamide)      Carbidopa      Interferon alpha      Levodopa      Interleukin 2 (Aldesleukin)      Peginterferon alfa-2a      Pramipexole      Rasagiline      Immunosuppressants Ropinirole      Anti-thymocyte globulin      Azathioprine      Steroids Basiliximab      Beclometasone      Belatacept      Betamethasone           Budesonide      Mycophenolate      Clobetasol      For personal use only. Not for distribution. for distribution. Not only. use For personal Sirolimus      Dexamethasone      Tacrolimus      Fludrocortisone      Lipid Lowering Agents Fluocinolone      Fluticasone Atorvastatin           Bezafibrate      Hydrocortisone (oral)      Clofibrate      Hydrocortisone (topical)      Ezetimibe      Megestrol acetate      Fenofibrate      Methylprednisolone      Fish oils      Mometasone      Fluvastatin      Nandrolone      Gemfibrozil      Oxandrolone      Lovastatin      Prednisolone      Pitavastatin      Prednisone      Pravastatin      Stanazolol      Rosuvastatin      Testosterone      Simvastatin      Triamcinolone     

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and EFV Efavirenz (Sustiva®, Stocrin®)  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. Potential interaction – may require close monitoring, ® ETV Etravirine (Intelence )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool Potential interaction likely to be of weak intensity. ® Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF NVP Nevirapine (Viramune ) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge RPV Rilpivirine (Edurant®) unlikely to be required and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any RPV + Rilpivirine/Emtricitabine/Tenofovir alafenamide There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude F/TAF (Odefsey ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ddI ddI d4T d4T 3TC 3TC FTC TDF FTC TDF ZDV ZDV ABC ABC F/TAF F/TAF Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium         Ertapenem         Bupivacaine         Erythromycin         Cisatracurium         Ethambutol         Desflurane         Ethionamide         Dexmedetomidine         Flucloxacillin         Enflurane         Gentamicin         Ephedrine         Imipenem/Cilastatin         Halothane         Isoniazid         Isoflurane         Kanamycin         Levofloxacin         Ketamine         Linezolid         Nitrous oxide         Meropenem         Propofol         Metronidazole         Rocuronium         Moxifloxacin         Sevoflurane         Nitrofurantoin         Sufentanil         Ofloxacin         Suxamethonium (succinylcholine)         Para-aminosalicylic acid         Tetracaine         Penicillins        

Thiopental         distribution. for Pyrazinamide         Tizanidine         Rifabutin         Vecuronium         Rifampicin         Analgesics Rifapentine         Alfentanil         Rifaximin         Aspirin         Spectinomycin         Buprenorphine         Streptomycin         Celecoxib         Sulfadiazine         Telithromycin         Codeine         Tetracyclines         Dextropropoxyphene         Trimethoprim/Sulfamethoxazole         Diamorphine (diacetylmorphine)         Vancomycin         Diclofenac         Dihydrocodeine         Anti-coagulant, Anti-platelet and Fibrinolytic Acenocoumarol Fentanyl                 Apixaban         Hydrocodone         Aspirin (anti-platelet)         Hydromorphone         Clopidogrel         Ibuprofen         Dabigatran         Mefenamic acid         Dalteparin         Methadone         Dipyridamole        

Morphine         Not only. use For personal istribution. Edoxaban         Naproxen         Eltrombopag         Nimesulide         Enoxaparin         Oxycodone         Fondaparinux         Paracetamol (Acetaminophen)         Heparin         Pethidine (Meperidine)         Phenprocoumon         Piroxicam         Prasugrel         Tramadol         Rivaroxaban         Streptokinase         Antihelmintics Albendazole         Ticagrelor         Warfarin         Diethylcarbamazine         Ivermectin         Anticonvulsants Levamisole (Ergamisol)         Carbamazepine         Mebendazole         Clonazepam         Niclosamide         Ethosuximide         Oxamniquine         Gabapentin         Lacosamide         Praziquantel         Lamotrigine         Pyrantel         Levetiracetam         Suramin sodium         Oxcarbazepine         Triclabendazole         Phenobarbital (Phenobarbitone)         Antiarrhythmics Phenytoin         Amiodarone         Pregabalin         Bepridil         Topiramate         Disopyramide         Valproate (Divalproex)         Dofetilide         Vigabatrin         Flecainide         Zonisamide         Lidocaine (Lignocaine)         Antidepressants Mexiletine         Agomelatine         Propafenone         Amitriptyline         Quinidine         Bupropion         Citalopram         Antibacterials Amikacin         Clomipramine         Desipramine         Amoxicillin         Doxepin         Ampicillin         Duloxetine         Azithromycin         Escitalopram         Bedaquiline         Fluoxetine         For personal use only. Not for distribution. For personal use only. Not for d Not only. use For personal for distribution. Not only. use For personal Capreomycin         Fluvoxamine         Cefalexin         Imipramine         Cefazolin         Lithium         Cefixime         Maprotiline         Cefotaxime                 Ceftazidime         Milnacipran         Ceftriaxone         Mirtazapine         Chloramphenicol         Nefazodone         Ciprofloxacin         Nortriptyline         Clarithromycin         Paroxetine         Clavulanic acid         Phenelzine         Clindamycin         Reboxetine         Clofazimine         Sertraline         Cloxacillin         Tranylcypromine         Cycloserine         Trazodone         Dapsone         Trimipramine         Doxycycline         Venlafaxine        

Key to abbreviations Key to symbols ® Where advice differs between countries, and/or between boosted and ABC (Ziagen )  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. ® ® ddI (Videx , Videx-EC ) Potential interaction – may require close monitoring, ®  alteration of drug dosage or timing of administration FTC Emtricitabine (Emtriva ) © Liverpool Drug Interactions Group, University of Liverpool ® Potential interaction likely to be of weak intensity. F/TAF Emtricitabine + Tenofovir alafenamide (Descovy ) Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® Additional action/monitoring or dosage adjustment is 3TC (Epivir ) unlikely to be required We aim to ensure that information is accurate and consistent with current knowledge d4T (Zerit®) and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this TDF fumarate (Viread®) There are no clear data, actual or theoretical, to indicate publication whether arising from negligence or otherwise howsoever or for any ZDV (Retrovir®)  whether an interaction will occur consequences arising therefrom. The University of Liverpool expressly exclude

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 2 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ddI ddI d4T d4T 3TC 3TC FTC TDF FTC TDF ZDV ZDV ABC ABC F/TAF F/TAF Anti-diabetics Antipsychotics/Neuroleptics Acarbose         Amisulpride         Empagliflozin         Aripiprazole         Exanatide         Asenapine         Chlorpromazine         Glibenclamide (Glyburide)         Clozapine         Gliclazide         Fluphenazine         Glimepiride         Haloperidol         Glipizide         Iloperidone         Insulin         Levomepromazine         Linagliptin         Olanzapine        

Liraglutide         Paliperidone         Perazine         Metformin         Pericyazine         Nateglinide         Perphenazine         Pioglitazone         Pimozide         Repaglinide         Pipotiazine         Rosiglitazone         Quetiapine         Saxagliptin         distribution. for Risperidone         Sitagliptin         Sulpiride         Thioridazine         Tolbutamide         Tiapride         Vildagliptin         Ziprasidone         Antifungals Zotepine         Amphotericin B         Zuclopenthixol         Anidulafungin         Antivirals Caspofungin         Aciclovir         Fluconazole         Adefovir         Flucytosine         Amantadine         Boceprevir         Griseofulvin         Cidofovir         Itraconazole         Daclatasvir         Ketoconazole         Elbasvir/Grazoprevir         Miconazole         Entecavir         Nystatin         Famciclovir         Posaconazole         Foscarnet         Ganciclovir         Terbinafine         Not only. use For personal istribution. Voriconazole         Glecaprevir/Pibrentasvir         Antihistamines Ledipasvir/Sofosbuvir         Ombitasvir/Paritaprevir/r         Astemizole         Ombitasvir/Paritaprevir/r + Dasabuvir         Cetirizine         Oseltamivir         Chlorphenamine         Ribavirin         Diphenhydramine         Rimantadine         Fexofenadine         Simeprevir         Levocetirizine         Sofosbuvir         Loratadine         Sofosbuvir/Velpatasvir         Promethazine         Sofosbuvir/Velpatasvir/Voxilaprevir         Telaprevir         Terfenadine         Telbivudine         Antimigraine Agents Valaciclovir         Almotriptan         Zanamivir         Dihydroergotamine         Anxiolytics/Hypnotics/ Sedatives Ergotamine         Alprazolam         Rizatriptan         Bromazepam         Sumatriptan         Buspirone         Chlordiazepoxide         Antiprotozoals Clorazepate         Amodiaquine         Diazepam         Artemisinin         Estazolam         Atovaquone         Flunitrazepam         Benznidazole         Flurazepam         Chloroquine         Hydroxyzine         Lorazepam         Diloxanide         Lormetazepam         Eflornithine         Midazolam (oral)         Halofantrine         Midazolam (parenteral)         Lumefantrine         Oxazepam         Mefloquine         Temazepam         Meglumine antimoniate         Triazolam         Melarsoprol         Zaleplon         Zolpidem        

Miltefosine         for d Not only. use For personal for distribution. Not only. use For personal Zopiclone         Nifurtimox         Beta Blockers Paromomycin         Atenolol         Pentamidine         Bisoprolol         Primaquine         Carvedilol         Proguanil         Metoprolol         Pyrimethamine         Nebivolol         Oxprenolol         Quinine         Pindolol         Sodium stibogluconate         Propranolol         Sulfadoxine         Timolol        

Key to abbreviations Key to symbols ® Where advice differs between countries, and/or between boosted and ABC Abacavir (Ziagen )  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. ® ® ddI Didanosine (Videx , Videx-EC ) Potential interaction – may require close monitoring, ®  alteration of drug dosage or timing of administration FTC Emtricitabine (Emtriva ) © Liverpool Drug Interactions Group, University of Liverpool ® Potential interaction likely to be of weak intensity. F/TAF Emtricitabine + Tenofovir alafenamide (Descovy ) Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® Additional action/monitoring or dosage adjustment is 3TC Lamivudine (Epivir ) unlikely to be required We aim to ensure that information is accurate and consistent with current knowledge d4T Stavudine (Zerit®) and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this TDF Tenofovir disoproxil fumarate (Viread®) There are no clear data, actual or theoretical, to indicate publication whether arising from negligence or otherwise howsoever or for any ZDV Zidovudine (Retrovir®)  whether an interaction will occur consequences arising therefrom. The University of Liverpool expressly exclude

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 3 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ddI ddI d4T d4T 3TC 3TC FTC TDF FTC TDF ZDV ZDV ABC ABC F/TAF F/TAF Bronchodilators Cytotoxics (continued) Aclidinium bromide         Mercaptopurine         Aminophylline         Mesna         Formoterol         Methotrexate         Glycopyrronium bromide         Mitoxantrone         Indacaterol         Nilotinib         Ipratropium bromide         Oxaliplatin         Montelukast         Paclitaxel         Olodaterol         Pazopanib         Roflumilast         Procarbazine         Salbutamol         Rituximab         Salmeterol         Sorafenib         Theophylline         Sunitinib         Tiotropium bromide         Tamoxifen         Umeclidinium bromide         Temsirolimus         Vilanterol         Topotecan         Toremifene         Calcium Channel Blockers Amlodipine         Vinblastine        

Diltiazem         distribution. for Vincristine         Vorinostat Felodipine                 Nicardipine         Erectile Dysfunctional Agents Nifedipine         Sildenafil (Erectile Dysfunction)         Nisoldipine         Tadalafil (Erectile Dysfunction)         Nitrendipine         Vardenafil         Verapamil         Gastrointestinal Agents Contraceptives/HRT Alosetron         Desogestrel (COC)         Aluminium hydroxide         Desogestrel (POP)         Antacids         Drospirenone (COC)         Bisacodyl         Drospirenone (HRT)         Cimetidine         Dydrogesterone (HRT)         Cisapride         Estradiol         Esomeprazole         Ethinylestradiol         Famotidine         Etonogestrel (implant)         Lactulose         Etonogestrel (vaginal ring)         Lansoprazole         Gestodene (COC)         Loperamide         Levonorgestrel (COC)         Mesalazine         istribution. For personal use only. Not Not only. use For personal istribution. Omeprazole Levonorgestrel (emergency contraception)                 Pantoprazole         Levonorgestrel (HRT)         Prucalopride         Levonorgestrel (implant)         Rabeprazole         Levonorgestrel (IUD)         Ranitidine         Levonorgestrel (POP)         Senna         Medroxyprogesterone (depot injection)         Medroxyprogesterone (oral)         Gastrointestinal Agents (anti-emetics) Norelgestromin (patch)         Aprepitant         Norethisterone [Norethindrone] (COC)         Dolasetron         Norethisterone [Norethindrone] (HRT)         Domperidone         Norethisterone [Norethindrone] (IM depot)         Dronabinol         Norethisterone [Norethindrone] (POP)         Granisetron         Norgestimate (COC)         Metoclopramide         Norgestrel (COC)         Ondansetron         Norgestrel (HRT)         Prochlorperazine         Ulipristal         Herbals/Supplements/Vitamins African potato         Cytotoxics Anastrozole         Aloe vera         Ascorbic Acid (Vitamin C) Asparaginase                 Cat’s claw (Uncaria tomentosa) Bexarotene                 Colecalciferol (vitamin D3)         Bleomycin         Cubeb pepper (Piper cubeba)         Bortezomib         Cyanocobalamin         Capecitabine         Echinacea         Carboplatin         Eucalyptus globulus         Chlorambucil         Folic acid         Cisplatin         Garlic         Cyclophosphamide         Ginger (Zinigiber officinale)         Cytarabine         Ginkgo biloba         Dacarbazine         Goldenseal root (Hydrastis canadensis)         Dactinomycin         Grapefruit juice         Dasatinib         Hops (Humulus lupulus)         Daunorubicin         Inula racemosa         Docetaxel         Iodine         Doxorubicin         Iron supplements         Droloxifene         Liquorice (Glycyrrhiza glabra)         Epirubicin         for d Not only. use For personal for distribution. Not only. use For personal Malabar nut tree         Erlotinib         Menthol         Estramustine         Milk thistle         Etoposide         Nicotinamide         Everolimus         Phytomenadione (vitamin K)         Exemestane         Pyridoxine (vitamin B6)         Fludarabine         Quercetin         Fluorouracil         Retinol (vitamin A)         Formestane         Riboflavin (vitamin B2)         Gefitinib         Saw palmetto (Serenoa repens)         Gemcitabine         Seville orange juice         Ifosfamide         St John's Wort         Imatinib         Thiamine (vitamin B1)         Irinotecan         Turmeric (Curcuma longa)         Lapatinib         Valerian         Letrozole         Vitamin E        

Key to abbreviations Key to symbols ® Where advice differs between countries, and/or between boosted and ABC Abacavir (Ziagen )  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. ® ® ddI Didanosine (Videx , Videx-EC ) Potential interaction – may require close monitoring, ®  alteration of drug dosage or timing of administration FTC Emtricitabine (Emtriva ) © Liverpool Drug Interactions Group, University of Liverpool ® Potential interaction likely to be of weak intensity. F/TAF Emtricitabine + Tenofovir alafenamide (Descovy ) Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® Additional action/monitoring or dosage adjustment is 3TC Lamivudine (Epivir ) unlikely to be required We aim to ensure that information is accurate and consistent with current knowledge d4T Stavudine (Zerit®) and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this TDF Tenofovir disoproxil fumarate (Viread®) There are no clear data, actual or theoretical, to indicate publication whether arising from negligence or otherwise howsoever or for any ZDV Zidovudine (Retrovir®)  whether an interaction will occur consequences arising therefrom. The University of Liverpool expressly exclude

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with NRTIs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 4 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

ddI ddI d4T d4T 3TC 3TC FTC TDF FTC TDF ZDV ZDV ABC ABC F/TAF F/TAF Hypertension / Heart Failure Agents Other Aliskiren         Acetazolamide         Ambrisentan         Acitretin         Amiloride         Adrenaline (Epinephrine)         Bendroflumethiazide         Alendronic Acid         Bosentan         Alfuzosin         Candesartan         Allopurinol         Captopril         Atropine         Chlortalidone         Baclofen         Cilazapril         Biperiden         Clonidine         Caffeine citrate        

Digoxin         Calcium         Dopamine         Carbimazole         Doxazosin         Clomifene         Enalapril         Colchicine         Epoprostenol         Cyproterone acetate         Eprosartan         Denosumab         Furosemide         Disulfiram         Hydralazine         Dutasteride         Hydrochlorothiazide         distribution. for Finasteride         Iloprost         Flibanserin         Indapamide         Goserelin         Irbesartan         Ibandronic acid         Isosorbide dinitrate         Isotretinoin         Ivabradine         Leuprorelin         Labetalol         Levothyroxine         Lacidipine         Magnesium         Lercanidipine         Mannitol         Lisinopril         Methylphenidate         Losartan         Modafinil         Macitentan         Naftidrofuryl         Methyldopa         Naltrexone         Metolazone         Neostigmine         Olmesartan         Nicorandil         Perindopril         Orlistat         Prazosin         Penicillamine Quinapril                 Ramipril         Pentoxifylline         Ranolazine         Pilocarpine         Potassium        

Riociguat         Not only. use For personal istribution. Sacubitril         Probenecid         Selexipag         Propylthiouracil         Sildenafil (PAH)         Protamine sulphate         Sodium nitroprusside         Pyridostigmine         Spironolactone         Strontium ranelate         Tadalafil (PAH)         Sulfasalazine         Telmisartan         Tamsulosin         Terazosin         Thalidomide         Torasemide         Tranexamic acid         Trandolapril         Varenicline         Treprostinil         Zoledronic acid         Valsartan         Overactive Bladder Agents Xipamide         Darifenacin         Illicit/Recreational Fesoterodine         Alcohol         Mirabegron         Amphetamine         Oxybutynin         Cannabis         Solifenacin         Cocaine         Tolterodine         Ecstasy (MDMA)         Trospium         GHB (Gamma-hydroxybutyrate_         Oxytocics Heroin         Ergometrine (Ergonovine)         LSD (Lysergic acid diethylamide)         Mifepristone         Mephedrone         Misoprostol         Methamphetamine         Oxytocin         Phencyclidine (PCP)         Poppers(Amyl nitrate)         Parkinsonism Agents Immune Modulators Apomorphine         Benserazide         Hydroxyurea (Hydroxycarbamide)         Carbidopa         Interferon alpha         Levodopa Interleukin 2 (Aldesleukin)                 Peginterferon alfa-2a         Pramipexole         Rasagiline         Immunosuppressants Ropinirole         Anti-thymocyte globulin         Steroids Azathioprine         Beclometasone         Basiliximab         Belatacept         Betamethasone         Budesonide         Ciclosporin         for d Not only. use For personal for distribution. Not only. use For personal Mycophenolate         Clobetasol         Sirolimus         Dexamethasone         Tacrolimus         Fludrocortisone         Fluocinolone         Lipid Lowering Agents Fluticasone         Atorvastatin         Hydrocortisone (oral)         Bezafibrate         Hydrocortisone (topical)         Clofibrate         Megestrol acetate         Ezetimibe         Methylprednisolone         Fenofibrate         Mometasone         Fish oils         Nandrolone         Fluvastatin         Oxandrolone         Gemfibrozil         Prednisolone         Lovastatin         Pitavastatin         Prednisone         Pravastatin         Stanazolol         Rosuvastatin         Testosterone         Simvastatin         Triamcinolone         Key to abbreviations Key to symbols ® Where advice differs between countries, and/or between boosted and ABC Abacavir (Ziagen )  These drugs should not be coadministered unboosted regimens, the charts reflect the more cautious option. ® ® ddI Didanosine (Videx , Videx-EC ) Potential interaction – may require close monitoring, ®  alteration of drug dosage or timing of administration FTC Emtricitabine (Emtriva ) © Liverpool Drug Interactions Group, University of Liverpool ® Potential interaction likely to be of weak intensity. F/TAF Emtricitabine + Tenofovir alafenamide (Descovy ) Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF ® Additional action/monitoring or dosage adjustment is 3TC Lamivudine (Epivir ) unlikely to be required We aim to ensure that information is accurate and consistent with current knowledge d4T Stavudine (Zerit®) and practice. However, the University of Liverpool and its servants or agents shall not  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this TDF Tenofovir disoproxil fumarate (Viread®) There are no clear data, actual or theoretical, to indicate publication whether arising from negligence or otherwise howsoever or for any ZDV Zidovudine (Retrovir®)  whether an interaction will occur consequences arising therefrom. The University of Liverpool expressly exclude

liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Entry & Integrase Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BIC/ E/C/F/ E/C/F/ BIC/ E/C/F/ E/C/F/ F/TAF DTG TAF TDF MVC RAL F/TAF DTG TAF TDF MVC RAL Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium       Ertapenem       Bupivacaine       Erythromycin       Cisatracurium       Ethambutol       Desflurane       Ethionamide       Dexmedetomidine       Flucloxacillin       Enflurane       Gentamicin       Ephedrine       Imipenem/Cilastatin       Halothane       Isoniazid       Isoflurane       Kanamycin       Levofloxacin Ketamine             Linezolid       Nitrous oxide       Meropenem      

Propofol       Metronidazole       Rocuronium       Moxifloxacin       Sevoflurane       Nitrofurantoin       Sufentanil       Ofloxacin       Suxamethonium (succinylcholine)       Para-aminosalicylic acid       Tetracaine       Penicillins       Thiopental       Pyrazinamide       Tizanidine       Rifabutin       Vecuronium       Rifampicin       Analgesics Rifapentine       Alfentanil       Rifaximin       Aspirin       Spectinomycin       Buprenorphine       Streptomycin       Celecoxib       Sulfadiazine       Telithromycin Codeine             Tetracyclines       Dextropropoxyphene       Trimethoprim/Sulfamethoxazole       Diamorphine (diacetylmorphine)       Vancomycin       Diclofenac       Dihydrocodeine       Anti-coagulant, Anti-platelet and Fibrinolytic Fentanyl       Acenocoumarol       Hydrocodone       Apixaban       Aspirin (anti-platelet)       Hydromorphone       Clopidogrel       Ibuprofen       Dabigatran       Mefenamic acid       Dalteparin       Methadone       Dipyridamole       Morphine       Edoxaban       Naproxen       Eltrombopag       istribution. For personal use only. Not for distribution. for Not only. use For personal istribution. Nimesulide       Enoxaparin       Oxycodone       Fondaparinux       Paracetamol (Acetaminophen)       Heparin       Pethidine (Meperidine)       Phenprocoumon       Piroxicam       Prasugrel       Tramadol       Rivaroxaban       Anthelmintics Streptokinase       Albendazole       Ticagrelor       Diethylcarbamazine       Warfarin       Ivermectin       Anticonvulsants Levamisole (Ergamisol)       Carbamazepine       Mebendazole       Clonazepam       Niclosamide       Ethosuximide       Oxamniquine       Gabapentin       Praziquantel       Lacosamide       Pyrantel       Lamotrigine       Suramin sodium       Levetiracetam       Oxcarbazepine       Triclabendazole       Phenobarbital (Phenobarbitone)       Antiarrhythmics Phenytoin       Amiodarone       Pregabalin       Bepridil       Topiramate      

Disopyramide       for d Not only. use For personal distribution. Valproate (Divalproex)       Dofetilide       Vigabatrin       Flecainide       Zonisamide       Lidocaine (Lignocaine)       Antidepressants Mexiletine       Agomelatine       Propafenone       Amitriptyline       Quinidine       Bupropion       Antibacterials Citalopram       Amikacin       Clomipramine       Amoxicillin       Desipramine       Ampicillin       Doxepin       Azithromycin       Duloxetine       Bedaquiline       Escitalopram       Capreomycin       Fluoxetine       Fluvoxamine      

Cefalexin       for Not only. use For personal Imipramine Cefazolin             Lithium       Cefixime       Maprotiline       Cefotaxime       Mianserin       Ceftazidime       Milnacipran       Ceftriaxone       Mirtazapine       Chloramphenicol       Nefazodone       Ciprofloxacin       Nortriptyline       Clarithromycin       Paroxetine       Clavulanic acid       Phenelzine       Clindamycin       Reboxetine       Clofazimine       Sertraline       Cloxacillin       Tranylcypromine       Cycloserine       Trazodone       Dapsone       Trimipramine       Doxycycline       Venlafaxine      

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and + Emtricitabine +  These drugs should not be coadministered BIC/F/TAF Tenofovir alafenamide (Biktarvy®) unboosted regimens, the charts reflect the more cautious option. ® Potential interaction – may require close monitoring, DTG (Tivicay )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool + Cobicistat + Emtricitabine + Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF E/C/F/TAF Tenofovir alafenamide (Genvoya®) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge Elvitegravir + Cobicistat + Emtricitabine + unlikely to be required E/C/F/TDF ® and practice. However, the University of Liverpool and its servants or agents shall not Tenofovir disoproxil fumarate (Strilbild )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this ® ® publication whether arising from negligence or otherwise howsoever or for any MVC (Celsentri , Selzentry ) There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude RAL (Isentress ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Entry & Integrase Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 2 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BIC/ E/C/F/ E/C/F/ BIC/ E/C/F/ E/C/F/ F/TAF DTG TAF TDF MVC RAL F/TAF DTG TAF TDF MVC RAL Anti-diabetics Antipsychotics/Neuroleptics Acarbose       Amisulpride       Empagliflozin       Aripiprazole       Exanatide       Asenapine       Chlorpromazine       Glibenclamide (Glyburide)       Clozapine       Gliclazide       Fluphenazine       Glimepiride       Haloperidol       Glipizide       Iloperidone       Insulin       Levomepromazine       Linagliptin       Olanzapine       Liraglutide       Paliperidone      

Perazine       Metformin       Periciazine       Nateglinide       Perphenazine       Pioglitazone       Pimozide       Repaglinide       Pipotiazine       Rosiglitazone       Quetiapine       Saxagliptin       Risperidone       Sitagliptin       Sulpiride       Thioridazine       Tolbutamide       Tiapride       Vildagliptin       Ziprasidone       Antifungals Zotepine       Amphotericin B       Zuclopenthixol       Anidulafungin       Antivirals Caspofungin       Aciclovir       Fluconazole       Adefovir       Flucytosine       Amantadine       Boceprevir       Griseofulvin       Cidofovir       Itraconazole       Daclatasvir       Ketoconazole       Elbasvir/Grazoprevir       Miconazole       Entecavir       Nystatin       Famciclovir       Posaconazole       Foscarnet       Terbinafine       Ganciclovir       Voriconazole       Glecaprevir/Pibrentasvir       istribution. For personal use only. Not for distribution. for Not only. use For personal istribution. Antihistamines Ledipasvir/Sofosbuvir       Ombitasvir/Paritaprevir/r       Astemizole       Ombitasvir/Paritaprevir/r + Dasabuvir       Cetirizine       Oseltamivir       Chlorphenamine       Ribavirin       Diphenhydramine       Rimantadine       Fexofenadine       Simeprevir       Levocetirizine       Sofosbuvir       Loratadine       Sofosbuvir/Velpatasvir       Promethazine       Sofosbuvir/Velpatasvir/Voxilaprevir       Telaprevir       Terfenadine       Telbivudine       Antimigraine Agents Valaciclovir       Almotriptan       Zanamivir       Dihydroergotamine       Anxiolytics/Hypnotics/ Sedatives Ergotamine       Alprazolam       Rizatriptan       Bromazepam       Sumatriptan       Buspirone       Antiprotozoals Chlordiazepoxide       Clorazepate       Amodiaquine       Diazepam       Artemisinin       for d Not only. use For personal distribution. Estazolam       Atovaquone       Flunitrazepam       Benznidazole       Flurazepam       Chloroquine       Hydroxyzine       Diloxanide       Lorazepam       Eflornithine       Lormetazepam       Midazolam (oral)       Halofantrine       Midazolam (parenteral)       Lumefantrine       Oxazepam       Mefloquine       Temazepam       Meglumine antimoniate       Triazolam       Melarsoprol       Zaleplon       Miltefosine       Zolpidem       Nifurtimox       Zopiclone       For personal use only. Not for Not only. use For personal Paromomycin       Beta Blockers Pentamidine       Atenolol       Bisoprolol       Primaquine       Carvedilol       Proguanil       Metoprolol       Pyrimethamine       Nebivolol       Quinine       Oxprenolol       Sodium stibogluconate       Pindolol       Sulfadoxine       Propranolol       Timolol      

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and Bictegravir + Emtricitabine +  These drugs should not be coadministered BIC/F/TAF Tenofovir alafenamide (Biktarvy®) unboosted regimens, the charts reflect the more cautious option. ® Potential interaction – may require close monitoring, DTG Dolutegravir (Tivicay )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool Elvitegravir + Cobicistat + Emtricitabine + Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF E/C/F/TAF Tenofovir alafenamide (Genvoya®) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge Elvitegravir + Cobicistat + Emtricitabine + unlikely to be required E/C/F/TDF ® and practice. However, the University of Liverpool and its servants or agents shall not Tenofovir disoproxil fumarate (Strilbild )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this ® ® publication whether arising from negligence or otherwise howsoever or for any MVC Maraviroc (Celsentri , Selzentry ) There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude RAL Raltegravir (Isentress ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Entry & Integrase Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 3 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BIC/ E/C/F/ E/C/F/ BIC/ E/C/F/ E/C/F/ F/TAF DTG TAF TDF MVC RAL F/TAF DTG TAF TDF MVC RAL Bronchodilators Cytotoxics (continued) Aclidinium bromide       Mercaptopurine       Aminophylline       Mesna       Formoterol       Methotrexate       Glycopyrronium bromide       Mitoxantrone       Indacaterol       Nilotinib       Ipratropium bromide       Oxaliplatin       Montelukast       Paclitaxel       Olodaterol       Pazopanib       Roflumilast       Procarbazine       Salbutamol       Rituximab       Salmeterol       Sorafenib      

Theophylline       Sunitinib       Tiotropium bromide       Tamoxifen       Umeclidinium bromide       Temsirolimus       Vilanterol       Topotecan       Calcium Channel Blockers Toremifene       Vinblastine       Amlodipine       Vincristine       Diltiazem       Vorinostat       Felodipine       Nicardipine       Erectile Dysfunctional Agents Nifedipine       Sildenafil (Erectile Dysfunction)       Nisoldipine       Tadalafil (Erectile Dysfunction)       Nitrendipine       Vardenafil       Verapamil       Gastrointestinal Agents Contraceptives/HRT Alosetron       Desogestrel (COC)       Aluminium hydroxide       Desogestrel (POP)       Antacids       Drospirenone (COC)       Bisacodyl       Drospirenone (HRT)       Cimetidine       Cisapride Dydrogesterone (HRT)             Esomeprazole Estradiol             Famotidine       Ethinylestradiol       Lactulose       Etonogestrel (implant)       Lansoprazole       Etonogestrel (vaginal ring)       Loperamide       Gestodene (COC)       Mesalazine       Levonorgestrel (COC)       Omeprazole       Levonorgestrel (emergency contraception)       Pantoprazole       Levonorgestrel (HRT)       distribution. for Not only. use For personal istribution. Prucalopride       Levonorgestrel (implant)       Rabeprazole       Levonorgestrel (IUD)       Ranitidine       Levonorgestrel (POP)       Senna       Medroxyprogesterone (depot injection)       Medroxyprogesterone (oral)       Gastrointestinal Agents (anti-emetics) Norelgestromin (patch)       Aprepitant       Norethisterone [Norethindrone] (COC)       Dolasetron       Norethisterone [Norethindrone] (HRT)       Domperidone       Norethisterone [Norethindrone] (IM depot)       Dronabinol       Granisetron Norethisterone [Norethindrone] (POP)             Metoclopramide       Norgestimate (COC)       Ondansetron       Norgestrel (COC)       Prochlorperazine       Norgestrel (HRT)       Ulipristal       Herbals/Supplements/Vitamins Cytotoxics African potato       Aloe vera       Anastrozole       Ascorbic Acid (Vitamin C)       Asparaginase       Cat’s claw (Uncaria tomentosa)       Bexarotene       Colecalciferol (vitamin D3)       Bleomycin       Cubeb pepper (Piper cubeba)       Bortezomib       Cyanocobalamin      

Capecitabine       for d Not only. use For personal distribution. Echinacea       Carboplatin       Eucalyptus globulus       Chlorambucil       Folic acid       Cisplatin       Garlic       Cyclophosphamide       Ginger (Zinigiber officinale)       Cytarabine       Ginkgo biloba       Dacarbazine       Goldenseal root (Hydrastis canadensis)       Dactinomycin       Grapefruit juice       Dasatinib       Hops (Humulus lupulus)       Daunorubicin       Inula racemosa       Docetaxel       Iodine       Doxorubicin       Iron supplements       Droloxifene       Liquorice (Glycyrrhiza glabra)       Epirubicin       Malabar nut tree       Erlotinib       For personal use only. Not for Not only. use For personal Menthol       Estramustine       Milk thistle       Etoposide       Nicotinamide       Everolimus       Phytomenadione (vitamin K)       Exemestane       Pyridoxine (vitamin B6)       Fludarabine       Quercetin       Fluorouracil       Retinol (vitamin A)       Formestane       Riboflavin (vitamin B2)       Gefitinib       Saw palmetto (Serenoa repens)       Gemcitabine       Seville orange juice       Ifosfamide       St John's Wort       Imatinib       Thiamine (vitamin B1)       Irinotecan       Turmeric (Curcuma longa)       Lapatinib       Valerian       Letrozole       Vitamin E      

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and Bictegravir + Emtricitabine +  These drugs should not be coadministered BIC/F/TAF Tenofovir alafenamide (Biktarvy®) unboosted regimens, the charts reflect the more cautious option. ® Potential interaction – may require close monitoring, DTG Dolutegravir (Tivicay )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool Elvitegravir + Cobicistat + Emtricitabine + Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF E/C/F/TAF Tenofovir alafenamide (Genvoya®) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge Elvitegravir + Cobicistat + Emtricitabine + unlikely to be required E/C/F/TDF ® and practice. However, the University of Liverpool and its servants or agents shall not Tenofovir disoproxil fumarate (Strilbild )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this ® ® publication whether arising from negligence or otherwise howsoever or for any MVC Maraviroc (Celsentri , Selzentry ) There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude RAL Raltegravir (Isentress ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Entry & Integrase Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 4 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.

BIC/ E/C/F/ E/C/F/ BIC/ E/C/F/ E/C/F/ F/TAF DTG TAF TDF MVC RAL F/TAF DTG TAF TDF MVC RAL Hypertension / Heart Failure Agents Other Aliskiren       Acetazolamide       Ambrisentan       Acitretin       Amiloride       Adrenaline (Epinephrine)       Bendroflumethiazide       Alendronic Acid       Bosentan       Alfuzosin       Candesartan       Allopurinol       Captopril       Atropine       Chlortalidone       Baclofen       Cilazapril       Biperiden       Clonidine       Caffeine citrate       Digoxin       Calcium       Dopamine       Carbimazole       Doxazosin       Clomifene       Enalapril       Colchicine       Epoprostenol       Cyproterone acetate       Eprosartan       Denosumab       Furosemide       Disulfiram       Hydralazine       Dutasteride       Hydrochlorothiazide       Finasteride       Iloprost       Flibanserin       Indapamide       Goserelin       Irbesartan       Ibandronic acid       Isosorbide dinitrate       Isotretinoin       Ivabradine       Leuprorelin       Labetalol       Levothyroxine       Lacidipine       Magnesium       Lercanidipine       Mannitol       Lisinopril       Methylphenidate       Losartan       Modafinil       Macitentan       Naftidrofuryl       Methyldopa       Naltrexone       Metolazone       Neostigmine       Olmesartan       Nicorandil       Perindopril       Orlistat       Prazosin       Penicillamine       Quinapril       Pentoxifylline Ramipril             Ranolazine       Pilocarpine       Riociguat       Potassium       Sacubitril       Probenecid       Selexipag       distribution. for Not only. use For personal istribution. Propylthiouracil       Sildenafil (PAH)       Protamine sulphate       Sodium nitroprusside       Pyridostigmine       Spironolactone       Strontium ranelate       Tadalafil (PAH)       Sulfasalazine       Telmisartan       Tamsulosin       Terazosin       Thalidomide       Torasemide       Tranexamic acid       Trandolapril       Varenicline       Treprostinil       Zoledronic acid       Valsartan       Overactive Bladder Agents Xipamide       Darifenacin       Illicit/Recreational Fesoterodine       Alcohol       Mirabegron       Amphetamine       Oxybutnin       Cannabis       Solifenacin       Cocaine       Tolterodine       Ecstasy (MDMA)       Trospium       GHB (Gamma-hydroxybutyrate_       Oxytocics Heroin       Ergometrine (Ergonovine)       LSD (Lysergic acid diethylamide)       Mifepristone       Mephedrone       Misoprostol       Methamphetamine       distribution. For personal use only. Not for d Not only. use For personal distribution. Oxytocin       Phencyclidine (PCP)       Poppers(Amyl nitrate)       Parkinsonism Agents Immune Modulators Apomorphine       Benserazide       Hydroxyurea (Hydroxycarbamide)       Carbidopa       Interferon alpha       Levodopa       Interleukin 2 (Aldesleukin)       Peginterferon alfa-2a       Pramipexole       Rasagiline       Immunosuppressants Ropinirole       Anti-thymocyte globulin       Azathioprine       Steroids Basiliximab       Beclometasone       Belatacept       Betamethasone       Ciclosporin       Budesonide       Mycophenolate       Clobetasol       Sirolimus       for Not only. use For personal Dexamethasone       Tacrolimus       Fludrocortisone       Fluocinolone       Lipid Lowering Agents Atorvastatin       Fluticasone       Bezafibrate       Hydrocortisone (oral)       Clofibrate       Hydrocortisone (topical)       Ezetimibe       Megestrol acetate       Fenofibrate       Methylprednisolone       Fish oils       Mometasone       Fluvastatin       Nandrolone       Gemfibrozil       Oxandrolone       Lovastatin       Prednisolone       Pitavastatin       Prednisone       Pravastatin       Stanazolol       Rosuvastatin       Testosterone       Simvastatin       Triamcinolone      

Key to abbreviations Key to symbols Where advice differs between countries, and/or between boosted and Bictegravir + Emtricitabine +  These drugs should not be coadministered BIC/F/TAF Tenofovir alafenamide (Biktarvy®) unboosted regimens, the charts reflect the more cautious option. ® Potential interaction – may require close monitoring, DTG Dolutegravir (Tivicay )  alteration of drug dosage or timing of administration © Liverpool Drug Interactions Group, University of Liverpool Elvitegravir + Cobicistat + Emtricitabine + Potential interaction likely to be of weak intensity. Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF E/C/F/TAF Tenofovir alafenamide (Genvoya®) Additional action/monitoring or dosage adjustment is We aim to ensure that information is accurate and consistent with current knowledge Elvitegravir + Cobicistat + Emtricitabine + unlikely to be required E/C/F/TDF ® and practice. However, the University of Liverpool and its servants or agents shall not Tenofovir disoproxil fumarate (Strilbild )  No clinically significant interaction expected be responsible or in any way liable for the continued currency of information in this ® ® publication whether arising from negligence or otherwise howsoever or for any MVC Maraviroc (Celsentri , Selzentry ) There are no clear data, actual or theoretical, to indicate ®  consequences arising therefrom. The University of Liverpool expressly exclude RAL Raltegravir (Isentress ) whether an interaction will occur liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hiv-druginteractions.org

Interactions with Antiretroviral Drugs Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 1

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

PROTEASE INHIBITORS NNRTIs NRTIs OTHER

TAF + ddI IDV d4T 3TC FPV LPV TPV EFV ETV FTC TDF ATV RTV ZDV RAL NVP RPV DRV SQV DTG ABC Cobi MVC RPV + RPV FTC/TAF BIC/F/TAF FTC E/C/F/TAF E/C/F/TDF

PIs Atazanavir        Cobicistat F       Darunavir  O      Fosamprenavir R      Indinavir       Lopinavir P      Ritonavir E      Saquinavir R      Tipranavir S      NNRTIs Efavirenz O      Etravirine N      Nevirapine A       Rilpivirine  L      Rilpivirine + FTC/TAF       NRTIs Abacavir (ABC)   U     Didanosine (ddI)  S     Emtricitabine (FTC)  E     Emtricitabine + TAF        Lamivudine (3TC)  O     Stavudine (d4T)  N     Tenofovir-DF (TDF)  L     Zidovudine (AZT/ZDV)  Y     Other Bictegravir/F/TAF       Dolutegravir      Elvitegravir/Cobi/F/TAF       Elvitegravir/Cobi/F/TDF       (T20)      Maraviroc      Raltegravir      For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. Key to symbols Co-formulations

 These drugs should not be coadministered Atripla® Efavirenz + Emtricitabine + Tenofovir-DF Potential interaction – may require close monitoring, alteration of drug dosage or Biktarvy® Bictegravir + Emtricitabine + Tenofovir alafenamide  timing of administration Potential interaction likely to be of weak intensity - additional action/monitoring or Combivir® Lamivudine + Zidovudine dosage adjustment is unlikely to be required Complera® Emtricitabine + Rilpivirine + Tenofovir-DF  No clinically significant interaction expected Descovy® Emtricitabine + Tenofovir alafenamide Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option. Eviplera® Emtricitabine + Rilpivirine + Tenofovir-DF Evotaz® Atazanavir + Cobicistat Key to abbreviations Genvoya® Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide ATV Atazanavir (Reyataz®) EFV Efavirenz (Sustiva®, Stocrin®) Juluca® Dolutegravir + Rilpivirine Cobi Cobicistat (Tybost®) ETV Etravirine (Intelence®) ® DRV Darunavir (Prezista®) NVP Nevirapine (Viramune®) Kivexa Abacavir + Lamivudine ® ® ® FPV Fosamprenavir (Telzir , Lexiva ) RPV Rilpivirine (Edurant ) Odefsey® Emtricitabine + Rilpivirine + Tenofovir alafenamide IDV Indinavir (Crixivan®) Prezcobix® Darunavir + Cobicistat LPV Lopinavir (Kaletra®) ABC Abacavir (Ziagen®) ® RTV Ritonavir (Norvir®) ddI Didanosine (Videx®, Videx-EC®) Rezolsta Darunavir + Cobicistat ® ® SQV Saquinavir (Invirase ) FTC Emtricitabine (Emtriva ) Symtuza® Darunavir + Cobicistat + Emtricitabine + Tenofovir alafenamide TPV Tipranavir (Aptivus®) 3TC Lamivudine (Epivir®) Stribild® Elvitegravir + Cobicistat + Emtricitabine + Tenofovir-DF d4T Stavudine (Zerit®) TAF Tenofovir alafenamide Triumeq® Abacavir + Lamivudine + Dolutegravir ® TDF Tenofovir disoproxil fumarate (Viread ) Trizivir® Abacavir + Lamivudine + Zidovudine ZDV Zidovudine (Retrovir®) ® Truvada Emtricitabine + Tenofovir-DF BIC/F/TAF Bictegravir + Emtricitabine + Tenofovir alafenamide DTG Dolutegravir (Tivicay®) E/C/F/TAF Elvitegravir + Cobicistat + Emtricitabine + Tenofovir alafenamide E/C/F/TDF Elvitegravir + Cobicistat + Emtricitabine+ Tenofovir disoproxil fumarate MVC Maraviroc (Celsentri®, Selzentry®) RAL Raltegravir (Isentress®) © Liverpool Drug Interactions Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF. We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Top View